| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ching-Hon Pui | Q66385450 |
| P2093 | author name string | Soheil Meshinchi | |
| Robert J Arceci | |||
| William L Carroll | |||
| P2860 | cites work | Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group | Q24602856 |
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome | Q24644436 | ||
| Treating childhood acute lymphoblastic leukemia without cranial irradiation | Q24644599 | ||
| A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study | Q24651897 | ||
| Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study | Q27824856 | ||
| Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. | Q27851476 | ||
| Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor | Q27851558 | ||
| Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study | Q27851561 | ||
| Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia | Q27851562 | ||
| Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia | Q28255265 | ||
| Tumor regression in cancer patients by very low doses of a T cell-engaging antibody | Q28290910 | ||
| Germline genomic variants associated with childhood acute lymphoblastic leukemia | Q28924384 | ||
| Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia | Q28943308 | ||
| Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia | Q29614324 | ||
| Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). | Q33645760 | ||
| Treatment strategy and long-term results in pediatric patients treated in two consecutive AML-GATLA trials | Q43753558 | ||
| Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia | Q43993658 | ||
| Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group | Q44158544 | ||
| Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia | Q44265478 | ||
| Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century | Q44586145 | ||
| Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen | Q44748439 | ||
| Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. | Q44844886 | ||
| Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22). | Q46497558 | ||
| Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group | Q46502896 | ||
| Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi | Q46530395 | ||
| Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96. | Q46656690 | ||
| Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report | Q46681659 | ||
| Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group | Q46761558 | ||
| Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials | Q46817257 | ||
| Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples | Q46932369 | ||
| In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid | Q47596252 | ||
| Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen | Q47812693 | ||
| AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features | Q47834838 | ||
| Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. | Q51975366 | ||
| Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. | Q52013638 | ||
| Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. | Q33645862 | ||
| Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001 | Q33647139 | ||
| FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. | Q33680292 | ||
| Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia | Q33733461 | ||
| Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. | Q33754603 | ||
| IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study | Q33897586 | ||
| Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. | Q33931890 | ||
| Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia | Q33985127 | ||
| Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report | Q34003323 | ||
| Chromosome translocations and covert leukemic clones are generated during normal fetal development | Q34032151 | ||
| Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. | Q34052581 | ||
| Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. | Q34080807 | ||
| Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. | Q34156717 | ||
| Leukaemogenesis: more than mutant genes | Q34275371 | ||
| DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. | Q34433577 | ||
| Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study | Q34570206 | ||
| Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet | Q34597535 | ||
| Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group | Q34645985 | ||
| Improved prognosis for older adolescents with acute lymphoblastic leukemia. | Q34679298 | ||
| Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group | Q34992080 | ||
| Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. | Q35209900 | ||
| Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia | Q35616085 | ||
| Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells | Q35847820 | ||
| Clinical implications of FLT3 mutations in pediatric AML. | Q35848876 | ||
| Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study | Q35848913 | ||
| KIR-incompatible hematopoietic-cell transplantation for poor prognosis infant acute lymphoblastic leukemia | Q35850044 | ||
| GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia | Q35897407 | ||
| The incidence and clinical significance of nucleophosmin mutations in childhood AML. | Q35901721 | ||
| Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia | Q35925016 | ||
| Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review | Q35944180 | ||
| The molecular basis of leukemia | Q35961770 | ||
| Treatment and prevention of tumor lysis syndrome in children. Experience of Associazione Italiana Ematologia Oncologia Pediatrica | Q35986905 | ||
| Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. | Q36141686 | ||
| Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. | Q52906615 | ||
| Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. | Q52906689 | ||
| Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. | Q52933515 | ||
| A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. | Q53232081 | ||
| Acute Megakaryoblastic Leukaemia: A National Clinical and Biological Study of 53 Adult and Childhood Cases by the Groupe Français d'Hématologie Cellulaire (GFHC) | Q53380738 | ||
| Acute lymphoblastic leukaemia | Q56722375 | ||
| Modeling of C/EBPα Mutant Acute Myeloid Leukemia Reveals a Common Expression Signature of Committed Myeloid Leukemia-Initiating Cells | Q57615422 | ||
| BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros | Q57734316 | ||
| Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia | Q58054015 | ||
| Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia | Q58054017 | ||
| Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group | Q58416054 | ||
| Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials | Q58481870 | ||
| Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials | Q73063060 | ||
| Nineteen cases of the t(1;22)(p13;q13) acute megakaryblastic leukaemia of infants/children and a review of 39 cases: report from a t(1;22) study group | Q73359118 | ||
| Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region | Q74267648 | ||
| Improved outcome after relapse in children with acute myeloid leukaemia | Q79719909 | ||
| Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML | Q79766644 | ||
| Acute lymphoblastic leukemia | Q79891876 | ||
| Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands | Q80860639 | ||
| Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results | Q81521487 | ||
| Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group | Q81585511 | ||
| Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: INS 84, 89 and 98 | Q82269132 | ||
| Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic | Q82269138 | ||
| Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML | Q82668142 | ||
| Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia | Q83244976 | ||
| Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol | Q84027433 | ||
| Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. | Q36246359 | ||
| Treatment of acute lymphoblastic leukemia | Q36366185 | ||
| Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group | Q36407162 | ||
| Treatment of children with acute promyelocytic leukemia: results of the first North American Intergroup trial INT0129 | Q36430103 | ||
| Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. | Q36430455 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review | Q36707825 | ||
| New therapeutic strategies for the treatment of acute lymphoblastic leukaemia | Q36724661 | ||
| What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies | Q36843677 | ||
| Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia | Q36969782 | ||
| A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects | Q37041909 | ||
| Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. | Q37059586 | ||
| Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia | Q37172988 | ||
| JAK mutations in high-risk childhood acute lymphoblastic leukemia | Q37224111 | ||
| Therapeutic targeting of MLL. | Q37234595 | ||
| The expanding role of arsenic in acute promyelocytic leukemia | Q37257316 | ||
| High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 | ||
| Acquired copy number alterations in adult acute myeloid leukemia genomes | Q37276767 | ||
| Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia | Q37276772 | ||
| The leukemic stem cell niche: current concepts and therapeutic opportunities | Q37295129 | ||
| Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. | Q37351577 | ||
| New genetic abnormalities and treatment response in acute lymphoblastic leukemia | Q37355964 | ||
| Treatment of childhood acute lymphoblastic leukemia | Q37355973 | ||
| Clinical implications of molecular genetic aberrations in acute myeloid leukemia | Q37363129 | ||
| Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study | Q37412290 | ||
| Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia | Q37440638 | ||
| Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects | Q37474395 | ||
| Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes | Q37654657 | ||
| Backtracking of leukemic clones to birth | Q38422434 | ||
| Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group | Q39766394 | ||
| Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options | Q39783711 | ||
| Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): long-term results of trials 82,85,89,92 and 97. | Q39918490 | ||
| Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia. | Q39928804 | ||
| Abundant anti-apoptotic BCL-2 is a molecular target in leukaemias with t(4;11) translocation | Q39990704 | ||
| The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors | Q40231262 | ||
| Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner | Q40270156 | ||
| KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival | Q40357255 | ||
| Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials | Q40370520 | ||
| Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. | Q40392434 | ||
| Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group | Q40394531 | ||
| ARID5B SNP rs10821936 is associated with risk of childhood acute lymphoblastic leukemia in blacks and contributes to racial differences in leukemia incidence | Q41922803 | ||
| Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. | Q43185220 | ||
| Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial | Q43206160 | ||
| Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. | Q43208675 | ||
| Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia | Q43217991 | ||
| Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. | Q43217994 | ||
| Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia | Q43221788 | ||
| Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). | Q43277746 | ||
| Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group | Q43701098 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 551-565 | |
| P577 | publication date | 2011-01-10 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Biology, risk stratification, and therapy of pediatric acute leukemias: an update | |
| P478 | volume | 29 |
| Q47131929 | (Immuno)proteasomes as therapeutic target in acute leukemia |
| Q37166753 | A 50-year journey to cure childhood acute lymphoblastic leukemia |
| Q35845024 | A Double Negative Loop Comprising ETV6/RUNX1 and MIR181A1 Contributes to Differentiation Block in t(12;21)-Positive Acute Lymphoblastic Leukemia |
| Q87182761 | A RAG driver on the road to pediatric ALL |
| Q52764412 | A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. |
| Q38403894 | A distinct DNA methylation signature defines pediatric pre-B cell acute lymphoblastic leukemia |
| Q55083557 | A greater birthweight increases the risk of acute leukemias in Mexican children-experience from the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia (MIGICCL). |
| Q26866379 | A health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigm |
| Q36009252 | A human ESC model for MLL-AF4 leukemic fusion gene reveals an impaired early hematopoietic-endothelial specification |
| Q33826848 | A novel self-lipid antigen targets human T cells against CD1c(+) leukemias |
| Q51058500 | A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigato |
| Q37471074 | A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group |
| Q58023761 | A somatic EZH2 mutation in childhood acute myeloid leukemia |
| Q34021009 | AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia |
| Q48375295 | ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis. |
| Q45355262 | Aberrant EPHB4 gene methylation and childhood acute lymphoblastic leukemia |
| Q37501821 | Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia |
| Q36141916 | Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia |
| Q47110817 | Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance |
| Q36285367 | Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia |
| Q39674477 | Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia |
| Q45309842 | Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma |
| Q41089816 | Acute Myeloid Leukemia with RAM Immunophenotype: A Pediatric Case with Unusual Morphologic Features |
| Q55292778 | Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled? |
| Q38479156 | Acute myeloid leukemia in infants: biology and treatment |
| Q64957945 | Adenosine Deaminase 1 as a Biomarker for Diagnosis and Monitoring of Patients with Acute Lymphoblastic Leukemia. |
| Q39208296 | Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy |
| Q33695967 | Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels |
| Q93013059 | Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation |
| Q36508630 | Advances in paediatric cancer treatment |
| Q36752634 | Advances in the Biology of Acute Lymphoblastic Leukemia-From Genomics to the Clinic |
| Q33878799 | Aleukaemic leukaemia presenting with pathological fracture |
| Q37017217 | Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia |
| Q88091540 | An overall characterization of pediatric acute lymphoblastic leukemia with CRLF2 overexpression |
| Q47806622 | Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards |
| Q92190307 | Association of genes ARID5B, CEBPE and folate pathway with acute lymphoblastic leukemia in a population from the Brazilian Amazon region |
| Q42706096 | Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia. |
| Q35210664 | Aurora kinases as druggable targets in pediatric leukemia: heterogeneity in target modulation activities and cytotoxicity by diverse novel therapeutic agents |
| Q41368368 | Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target |
| Q58088030 | Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1 driven B-cell precursor acute lymphoblastic leukemia |
| Q41913197 | Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine |
| Q38050656 | B-lineage transcription factors and cooperating gene lesions required for leukemia development |
| Q42573846 | BCOR and BCORL1 mutations in pediatric acute myeloid leukemia |
| Q42943355 | BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures |
| Q43092984 | BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group |
| Q92310059 | Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia |
| Q34755687 | Beyond the 2008 World Health Organization classification: the role of the hematopathology laboratory in the diagnosis and management of acute lymphoblastic leukemia |
| Q90341865 | Birthweight and all-cause mortality after childhood and adolescent leukemia: a cohort of children with leukemia from Denmark, Norway, Sweden, and Washington State |
| Q42021950 | Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia |
| Q91992439 | CD9 predicts ETV6-RUNX1 in childhood B-cell precursor acute lymphoblastic leukemia |
| Q53075287 | CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors. |
| Q35627570 | CREB and leukemogenesis |
| Q52671045 | CREB engages C/EBPδ to initiate leukemogenesis. |
| Q35602419 | Challenging issues in pediatric oncology |
| Q90135380 | Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia |
| Q27005960 | Childhood acute myeloid leukaemia |
| Q36322906 | Clinical and demographic characteristics of seasonal influenza in pediatric patients with cancer |
| Q39367965 | Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multi-institutional retrospective national collaborative study |
| Q54342441 | Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. |
| Q64286918 | Clinical utility of custom-designed NGS panel testing in pediatric tumors |
| Q35119306 | Cohort Profile: the French childhood cancer survivor study for leukaemia (LEA Cohort). |
| Q36053792 | Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia |
| Q59529214 | Cooperative genetic changes in pediatric B-cell precursor acute lymphoblastic leukemia with deletions or mutations ofIKZF1 |
| Q38079288 | Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission |
| Q39221970 | DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia |
| Q34228412 | DNA methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at remission |
| Q35129383 | DNA methylation-based subtype prediction for pediatric acute lymphoblastic leukemia |
| Q43004456 | DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T-cell acute lymphoblastic leukemia: an Italian study |
| Q53403193 | DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia. |
| Q40805012 | DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia |
| Q37665574 | Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes |
| Q36509641 | Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia |
| Q36100435 | Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia |
| Q39161651 | Determinants of quality of life during induction therapy in pediatric acute lymphoblastic leukemia |
| Q36528412 | Determination of ETV6-RUNX1 genomic breakpoint by next-generation sequencing |
| Q41444080 | Determination of Methotrexate, 7-Hydroxymethotrexate, and 2,4-Diamino-N10-methylpteroic Acid by LC-MS/MS in Plasma and Cerebrospinal Fluid and Application in a Pharmacokinetic Analysis of High-Dose Methotrexate |
| Q36303319 | Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group |
| Q37169331 | Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232 |
| Q89518213 | Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists |
| Q24310753 | Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia |
| Q36318780 | Does hematopoietic stem cell transplantation benefit infants with acute leukemia? |
| Q28538744 | Drug targets for cell cycle dysregulators in leukemogenesis: in silico docking studies |
| Q37185272 | Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML. |
| Q39440247 | Dysregulation of BCL-2 family proteins by leukemia fusion genes |
| Q34306768 | EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia. |
| Q53062739 | EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion. |
| Q52882383 | ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. |
| Q53098890 | EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia. |
| Q92059824 | Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia |
| Q101123793 | Effects of NT5C2 germline variants on 6-mecaptopurine metabolism in children with acute lymphoblastic leukemia |
| Q28831371 | Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells |
| Q35740058 | Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. |
| Q39032580 | Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia |
| Q47654837 | EgoNet identifies differential ego-modules and pathways related to prednisolone resistance in childhood acute lymphoblastic leukemia |
| Q26770327 | Emerging technologies in paediatric leukaemia |
| Q35661991 | Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia |
| Q34647168 | Epidemiology of childhood acute myeloid leukemia |
| Q38866662 | Epigenetic control of gene expression in leukemogenesis: Cooperation between wild type MLL and MLL fusion proteins |
| Q33740709 | Epigenetic deregulation in pediatric acute lymphoblastic leukemia. |
| Q38871097 | Essential role for cyclic-AMP responsive element binding protein 1 (CREB) in the survival of acute lymphoblastic leukemia |
| Q31143912 | Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data |
| Q50559980 | Executive Dysfunction 25 Years after Treatment with Cranial Radiotherapy for Pediatric Lymphoid Malignancies. |
| Q35679720 | Expression of Ik6 and Ik8 Isoforms and Their Association with Relapse and Death in Mexican Children with Acute Lymphoblastic Leukemia |
| Q55434312 | Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia. |
| Q89678304 | First-line treatment failure in childhood acute lymphoblastic leukemia: The polish pediatric leukemia and lymphoma study group experience |
| Q43866819 | Focused screening of a panel of cancer-related genetic polymorphisms reveals new susceptibility loci for pediatric acute lymphoblastic leukemia. |
| Q90698064 | GEM on proliferation and apoptosis of childhood AL cells through inhibiting c-myc expression by upregulating miR-125a-3p |
| Q90469951 | Gastric carcinoma subsequent to myelodysplastic syndrome with t (1; 19) chromosome translocation: A rare case report and its potential mechanisms |
| Q47136441 | Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia |
| Q44591810 | Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. |
| Q38839019 | Genetic alterations in glucocorticoid signaling pathway components are associated with adverse prognosis in children with relapsed ETV6/RUNX1-positive acute lymphoblastic leukemia |
| Q47592832 | Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia |
| Q41407670 | Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival |
| Q37385311 | Genetic variation in the extended major histocompatibility complex and susceptibility to childhood acute lymphoblastic leukemia: a review of the evidence |
| Q34270304 | Genetically InFormed therapies--a "GIFT" for children with cancer |
| Q33585130 | Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia |
| Q34066349 | Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia |
| Q26829976 | Genomic profiling of B-progenitor acute lymphoblastic leukemia |
| Q38381463 | Genomics in acute lymphoblastic leukaemia: insights and treatment implications |
| Q33586588 | Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia |
| Q34500075 | Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study |
| Q91249010 | Global efforts toward the cure of childhood acute lymphoblastic leukaemia |
| Q49324130 | HPRT1 activity loss is associated with resistance to thiopurine in ALL. |
| Q34866042 | Health status utilities in pediatrics: a systematic review of acute lymphoblastic leukemia |
| Q36714994 | Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemia |
| Q48314617 | Hematopoietic stem cell transplantation in pediatric patients with acute myeloid leukemia without favorable cytogenetics. |
| Q41036515 | High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial |
| Q38301831 | High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. |
| Q33667247 | High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome |
| Q34645259 | High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant? |
| Q36178314 | High-throughput screening in niche-based assay identifies compounds to target preleukemic stem cells. |
| Q44035793 | Hmga1 is differentially expressed and mediates silencing of the CD4/CD8 loci in T cell lineages and leukemic cells. |
| Q64117729 | Homozygous mutation in NUDT15 in childhood acute lymphoblastic leukemia with increased susceptibility to mercaptopurine toxicity: A case report |
| Q37650740 | Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia |
| Q26992280 | How I treat pediatric acute myeloid leukemia |
| Q45594506 | How disease advocacy organizations participate in clinical research: a survey of genetic organizations |
| Q24568045 | How do we prepare ourselves for a new paradigm of medicine to advance the treatment of pediatric acute lymphoblastic leukemia? |
| Q35180032 | Human leukocyte antigen-DRB1 polymorphism in childhood acute lymphoblastic leukemia |
| Q33729914 | Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1. |
| Q39070526 | Hypoxia-related gene expression profile in childhood acute lymphoblastic leukemia: prognostic implications |
| Q96616528 | Ibrutinib is not an effective drug in primografts of TCF3-PBX1 |
| Q38963879 | Identification of mutant alleles of JAK3 in pediatric patients with acute lymphoblastic leukemia |
| Q41903687 | Identifying new targets in leukemogenesis using computational approaches |
| Q58861726 | Impact of IKZF1 deletions and PAX5 amplifications in pediatric B-cell precursor ALL treated according to NOPHO protocols |
| Q36442504 | Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial |
| Q38622686 | Improved outcome of childhood acute myeloid leukemia in an Eastern European country: Lithuanian experience |
| Q34679298 | Improved prognosis for older adolescents with acute lymphoblastic leukemia. |
| Q36134458 | Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy. |
| Q39166310 | Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. |
| Q91749435 | Increase of PRPP enhances chemosensitivity of PRPS1 mutant acute lymphoblastic leukemia cells to 5-Fluorouracil |
| Q37226741 | Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. |
| Q36811650 | Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China |
| Q38720972 | Inferring a role for methylation of intergenic DNA in the regulation of genes aberrantly expressed in precursor B-cell acute lymphoblastic leukemia |
| Q34459885 | Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia |
| Q35784497 | Inherited genetic variation in childhood acute lymphoblastic leukemia |
| Q39141522 | Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells |
| Q49787961 | Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia |
| Q45351191 | Initial frequency of CD34+/CD38 - cells is not correlated with minimal residual disease level in 73 Chinese children with B-cell precursor acute lymphoblastic leukemia |
| Q38984055 | Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia. |
| Q40295439 | Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study |
| Q92417685 | Insights into the prenatal origin of childhood acute lymphoblastic leukemia |
| Q41473465 | Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia |
| Q42149280 | Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. |
| Q36592140 | Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth |
| Q41872478 | Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia |
| Q53085076 | Interrupted development of dentition in children receiving bone marrow transplantation for acute lymphocytic Leukemia: a case series. |
| Q36679531 | Intracellular Signaling Pathways Involved in Childhood Acute Lymphoblastic Leukemia; Molecular Targets |
| Q36751715 | Intrinsic and chemo-sensitizing activity of SMAC-mimetics on high-risk childhood acute lymphoblastic leukemia. |
| Q92903106 | Is Acute Myeloblastic Leukemia in Children Under 2 Years of Age a Specific Entity? A Report from the FRENCH ELAM02 Study Group |
| Q37379199 | L-Asparaginase Isolated from Phaseolus vulgaris Seeds Exhibited Potent Anti-Acute Lymphoblastic Leukemia Effects In-Vitro and Low Immunogenic Properties In-Vivo. |
| Q42369939 | Leukemia-Initiating Cells in T-Cell Acute Lymphoblastic Leukemia |
| Q50978065 | Leukemia-initiating cell activity requires calcineurin in T-cell acute lymphoblastic leukemia. |
| Q64120379 | Lipodystrophy-like features after total body irradiation among survivors of childhood acute leukemia |
| Q34221792 | Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome |
| Q47144324 | Low miR-210 and CASP8AP2 expression is associated with a poor outcome in pediatric acute lymphoblastic leukemia |
| Q55664929 | Low spontaneous apoptosis index at diagnosis predicts a high-risk phenotype in paediatric acute lymphoblastic leukaemia. |
| Q57815598 | Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations |
| Q41978213 | MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia. |
| Q37676956 | MLL-AF4 binds directly to a BCL-2 specific enhancer and modulates H3K27 acetylation |
| Q28658170 | MLL-rearranged acute lymphoblastic leukaemia stem cell interactions with bone marrow stroma promote survival and therapeutic resistance that can be overcome with CXCR4 antagonism |
| Q33762835 | Management of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. |
| Q38041467 | Management of small HER2 overexpressing tumours |
| Q38079075 | Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults |
| Q36425440 | Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia |
| Q89865097 | Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity |
| Q55033075 | Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. |
| Q46802244 | MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia |
| Q36413478 | MicroRNA biomarker identification for pediatric acute myeloid leukemia based on a novel bioinformatics model. |
| Q50959012 | Minimal residual disease of leukemia and the quality of cryopreserved human ovarian tissue in vitro. |
| Q38161393 | Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis |
| Q51711055 | Molecular characterization of KMT2A fusion partner genes in 13 cases of pediatric leukemia with complex or cryptic karyotypes. |
| Q37643136 | Molecular therapeutic approaches for pediatric acute myeloid leukemia |
| Q36339717 | Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia |
| Q39127003 | Mouse models of MLL leukemia: recapitulating the human disease |
| Q48178689 | Mutant PRPS1: a new therapeutic target in relapsed acute lymphoblastic leukemia |
| Q50614792 | Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia. |
| Q37592751 | NF-kappa B mediated up-regulation of CCCTC-binding factor in pediatric acute lymphoblastic leukemia |
| Q36892602 | NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia |
| Q50115786 | NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia. |
| Q52906780 | NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. |
| Q28115755 | NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity |
| Q44123939 | NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia |
| Q56960711 | NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group |
| Q55057111 | NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. |
| Q36873283 | Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia |
| Q36347988 | Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. |
| Q31167575 | Network Biomarkers Constructed from Gene Expression and Protein-Protein Interaction Data for Accurate Prediction of Leukemia |
| Q35192790 | Novel agents for the treatment of childhood acute leukemia |
| Q38500371 | Novel approaches to pediatric leukemia treatment |
| Q38094099 | Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies |
| Q38096798 | Novel therapies for children with acute myeloid leukaemia. |
| Q90355689 | Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia |
| Q55064299 | Optimal predictor for 6-mercaptopurine intolerance in Chinese children with acute lymphoblastic leukemia: NUDT15, TPMT, or ITPA genetic variants? |
| Q40314122 | Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia |
| Q47779465 | Osteonecrosis of the Shoulders in Pediatric Patients Treated for Leukemia or Lymphoma: Single-Institutional Experience |
| Q45236803 | Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America. |
| Q40681571 | Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial |
| Q54310310 | Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. |
| Q41021920 | Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia |
| Q38196743 | Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia |
| Q36317718 | PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity |
| Q37121686 | PACSIN2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy |
| Q57292246 | PAX5-ELN oncoprotein promotes multistep B-cell acute lymphoblastic leukemia in mice |
| Q33798890 | Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse |
| Q36163029 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? |
| Q35074246 | Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor |
| Q39425967 | Pediatric haematopoiesis and related malignancies |
| Q28391712 | Perspectives on the causes of childhood leukemia |
| Q36600202 | Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature |
| Q38186752 | Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies |
| Q34221738 | Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. |
| Q36161733 | Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group |
| Q49261196 | Phosphatase of regenerating liver-3 is expressed in acute lymphoblastic leukemia and mediates leukemic cell adhesion, migration and drug resistance |
| Q41178645 | Polymorphic variants of GSTM1, GSTT1, and GSTP1 genes in childhood acute leukemias: A preliminary study in Argentina |
| Q33914131 | Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia |
| Q28245060 | Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia |
| Q60170367 | Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia |
| Q56890609 | Preliminary investigation on the abnormal mechanism of CD4FOXP3CD25 regulatory T cells in pediatric B-cell acute lymphoblastic leukemia |
| Q48154097 | Prevalence and risk factors of cataract after chemotherapy with or without central nervous system irradiation for childhood acute lymphoblastic leukaemia: an LEA study |
| Q41869513 | Prevalence of gene rearrangements in Mexican children with acute lymphoblastic leukemia: a population study-report from the Mexican Interinstitutional Group for the identification of the causes of childhood leukemia |
| Q92481927 | Prognostic and therapeutic relevance of cathepsin B in pediatric acute myeloid leukemia |
| Q48231999 | Prognostic factors in canine acute leukaemias: a retrospective study. |
| Q35596960 | Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia |
| Q27851831 | Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia |
| Q34580110 | Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition |
| Q37815272 | Recent research advances in childhood acute lymphoblastic leukemia |
| Q39822035 | Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup study |
| Q36709009 | Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia |
| Q40273592 | Recurrent translocation t(10;17)(p15;q21) in minimally differentiated acute myeloid leukemia results in ZMYND11/MBTD1 fusion |
| Q26864460 | Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine |
| Q38818016 | Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia. |
| Q38377577 | Relapsed acute lymphoblastic leukemia with unusual multiple bone invasions: A case report |
| Q41560893 | Relationships of Human Leukocyte Antigen-A, -B, -DRB1 Alleles, and Haplotypes in 129 Ethnic Turkish Patients With Acute Myeloblastic Leukemia |
| Q52888397 | Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group. |
| Q36194222 | Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. |
| Q38264774 | Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention |
| Q98779175 | Role of microRNA dysregulation in childhood acute leukemias: Diagnostics, monitoring and therapeutics: A comprehensive review |
| Q38644266 | Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study |
| Q36580010 | Scaling up cancer care for children without medical insurance in developing countries: The case of Mexico. |
| Q26864522 | Second malignant neoplasms and cardiovascular disease following radiotherapy |
| Q36155399 | Self-Contained Statistical Analysis of Gene Sets |
| Q37131922 | Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group |
| Q48228311 | Sleep, fatigue, depression, and quality of life in survivors of childhood acute lymphoblastic leukemia |
| Q36924713 | Socioeconomic variation in survival from childhood leukaemia in northern England, 1968-2010. |
| Q36262391 | Space-Time Clustering of Childhood Leukemia: Evidence of an Association with ETV6-RUNX1 (TEL-AML1) Fusion |
| Q92525673 | Study protocol for a phase II, multicentre, prospective, non-randomised clinical trial to assess the safety and efficacy of infusing allogeneic activated and expanded natural killer cells as consolidation therapy for paediatric acute myeloblastic le |
| Q40874665 | Survival From Childhood Hematological Malignancies in Denmark: Is Survival Related to Family Characteristics? |
| Q92438795 | Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant |
| Q48123405 | Survivors of childhood and adolescent cancer: life-long risks and responsibilities |
| Q36967138 | Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood |
| Q40485655 | T-cell acute lymphoblastic leukemia in infants has distinct genetic and epigenetic features compared to childhood cases |
| Q47564553 | TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children |
| Q38371672 | Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial. |
| Q91711797 | Targeted Therapies for Pediatric AML: Gaps and Perspective |
| Q36989223 | Targeted drug discovery for pediatric leukemia |
| Q38214772 | Targeted nanoparticles for pediatric leukemia therapy |
| Q52375473 | Targeting Leukemia Stem Cells in the Bone Marrow Niche. |
| Q47580446 | Targeting acute myeloid leukemia by drug-induced c-MYB degradation |
| Q104073619 | Targeting aurora kinases as a potential prognostic and therapeutical biomarkers in pediatric acute lymphoblastic leukaemia |
| Q35334436 | Targeting cell cycle regulators in hematologic malignancies. |
| Q35176311 | Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model |
| Q35182716 | Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia |
| Q38017727 | Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies |
| Q92356480 | The AAA+ATPase RUVBL2 is essential for the oncogenic function of c-MYB in acute myeloid leukemia |
| Q53116139 | The Childhood Leukemia International Consortium. |
| Q90704717 | The Top 100 Highly Cited Original Articles on Immunotherapy for Childhood Leukemia |
| Q36745332 | The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. |
| Q64964729 | The case of undiagnosed immunodeficiency in child from mother with leukemia anamnesis. |
| Q95656564 | The impact of childhood cancer on parental separation, divorce, and family planning in Denmark |
| Q61445248 | The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL |
| Q89960668 | The lysine methyltransferase SMYD2 is required for normal lymphocyte development and survival of hematopoietic leukemias |
| Q34516051 | The molecular mechanics of mixed lineage leukemia |
| Q35023231 | The mutational landscape in pediatric acute lymphoblastic leukemia deciphered by whole genome sequencing |
| Q41099096 | The outcomes and treatment burden of childhood acute myeloid leukaemia in Australia, 1997-2008: A report from the Australian Paediatric Cancer Registry. |
| Q34380874 | The preparation of HL-60 cells vaccine expressing BCG heat shock protein 70 and detection of its immunogenicity in vitro |
| Q38833230 | The role of bortezomib in the treatment of acute lymphoblastic leukemia |
| Q38083796 | The role of chromatin remodeling in medulloblastoma. |
| Q41090525 | Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia |
| Q58492911 | Translokationen des MLL-Gens |
| Q37233236 | Transplant-related mortality following allogeneic hematopoeitic stem cell transplantation for pediatric acute lymphoblastic leukemia: 25-year retrospective review |
| Q48039932 | Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL-2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation |
| Q52626221 | Treatment outcome of children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group (TCCSG) Study L04-16. |
| Q42090608 | Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1 |
| Q28390558 | Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia |
| Q30979834 | Vy-PER: eliminating false positive detection of virus integration events in next generation sequencing data. |
| Q37060647 | What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia? |
| Q92354263 | Whole transcriptome sequencing reveals a KMT2A-USP2 fusion in infant acute myeloid leukemia |
| Q52814633 | Wogonoside exerts growth-suppressive effects against T acute lymphoblastic leukemia through the STAT3 pathway. |
| Q91861733 | [Bortezomib and obatoclax for dual blockade of protein degradation pathways show synergistic anti-tumor effect in human acute T lymphoblastic leukemia cells] |
| Q53742253 | [Genetic basis of leukemia: Serious consequences of chromosomal translocations]. |
| Q86478970 | [NT5C2 expression in children with acute leukemia and its clinical significance] |
| Q94589377 | [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia] |
| Q53064467 | [The prognostic significance of proportion of blasts in bone marrow on day 14 during induction chemotherapy in patients with adult Ph-negative acute lymphoblastic leukemia]. |
| Q90245131 | [Value of S100A8 in evaluating the prognosis of children with acute lymphoblastic leukemia] |
| Q33872395 | miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group |
| Q36546505 | t(17;19) in Children with Acute Lymphocytic Leukemia: A Report of 3 Cases and a Review of the Literature |
Search more.